## International Journal of COPD

#### Open Access Full Text Article

### CORRIGENDUM

# Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]

Ichinose M, Nishimura M, Akimoto M, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2147-2156.

On page 2152, Figure 3 should be presented as follows:

RR 0.71 (0.46, 1.10)\* 2.0 p=0.0434 Rate of COPD exacerbations 1.5 (per patient-year) 1.0 0.5 0.0 Moderate-to-severe exacerbations

Figure 3 Annualized rate of COPD exacerbations by treatment group.

Notes: Error bars represent the 99% CI for rate of moderate-to-severe COPD exacerbations and the 95% CI for rate of severe COPD exacerbations. Listed values are RR (CI: \*99% CI; ^95% CI), p-value. Negative binominal model, adjusted for treatment exposure. The duration of an event is not included in the calculation of a patient's exposure.

Abbreviations: OLO, olodaterol; TIO, tiotropium; RR, rate ratio.

### International Journal of COPD

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors

**Dove**press

3587

Submit your manuscript here: http://www.dovepress.com/international-iournal-of-chronic-obstructive-pulmonary-disease-iournal



International Journal of COPD 2018:13 3587

Commercial use of this work, is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0) License (http://creative.commons.org/licenses/by-nc/3.0/). By accessing the work you
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

RR 0.81 (0.51, 1.31)^ p=0.3924 Severe exacerbations 🛛 TIO 5 μg (n=235) 🔛 TIO+O 5/5 μg (n=226)